RCS - Angle PLC - ANGLE announces senior management appointments

AngleAnnouncement

05/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230605:nRSE5743Ba&default-theme=true

RNS Number : 5743B  Angle PLC  05 June 2023

 For immediate release   05 June 2023

 

ANGLE plc ("the Company")

 

ANGLE STRENGTHENS MANAGEMENT TEAM WITH SENIOR APPOINTMENTS

 

Brett Swansiger joins as Chief Commercial Officer

 

Karen Miller PhD joins as Chief Scientific Officer

 

 

 

ANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is
delighted to announce the appointments of Brett Swansiger as Chief Commercial
Officer (CCO) and Karen Miller PhD as Chief Scientific Officer (CSO). The
addition of these highly skilled and experienced leaders will further enhance
ANGLE's management team and support the Company in realising its commercial
potential.

 

Brett brings over 20 years of commercial leadership, international business
development, business-to-business sales and US managed care contracting
experience within the molecular diagnostic and pharmaceutical industries. Most
recently, Brett was CCO at DxTerity Diagnostics where he built out the
commercial organisation, established new business relationships and initiated
payer strategies. Brett began his life sciences career at Bristol Myers Squibb
before moving into senior commercial positions at Prometheus Laboratories,
Agendia Inc, and MDxHealth. Brett is based in the United States and is
responsible for managing pharma and clinical services sales, building
corporate partnerships globally, and for guiding US research and clinical
product sales and payer engagement. He also supports the products business
teams responsible for direct sales of products and sales through ANGLE's
growing distributor network.

 

Karen has over 30 years of experience in the pharmaceutical industry with an
extensive background in drug discovery and clinical development as well as
in-depth knowledge of molecular analysis techniques used for cancer analysis
in a wide range of indications with multiple modalities. She brings a strong
network of relationships within the pharmaceutical and companion diagnostic
industries. Karen was most recently CSO at Ixaka where she led research
strategy, guided major projects through to the clinic and participated in
partnership and licensing activities. Previous experience includes senior
executive positions with Vertex Pharmaceuticals, UCB Pharma, GlaxoSmithKline
and Adaptimmune. At ANGLE, Karen is responsible for external interactions with
pharma customers, medtech partner companies and laboratory customers to drive
the widespread adoption of the Parsortix system as well as providing overall
scientific leadership for the Company.

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"I am delighted to be able to welcome these two highly accomplished
individuals to the ANGLE management team. Brett and Karen bring valuable
skills and networks that will play a key role in helping us deliver on our
strategic and commercial objectives. I look forward to working closely with
them as we continue to build commercial momentum."

 

 

For further information:

 

 ANGLE plc                                   +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Andrew Holder, Head of Investor Relations

 Berenberg (NOMAD and Joint Broker)          +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                    +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin                  +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                    +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website
on https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc www.angleplc.com (http://www.angleplc.com)

ANGLE is a world leading liquid biopsy company with sample-to-answer
solutions. ANGLE's proven patent protected circulating tumor cell (CTC)
harvesting technology is known as the Parsortix(®) system.

 

ANGLE's Parsortix(®) system is FDA cleared for its intended use in metastatic
breast cancer and is currently the first and only FDA cleared medical device
to harvest intact circulating cancer cells from blood.

 

Intended use

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

The Parsortix PC1 system enables a liquid biopsy (a simple blood test) to be
used to provide the circulating tumor cells from metastatic breast cancer
patients to the user in a format suitable for multiple types of downstream
analyses. The system is based on a microfluidic device that captures cells
based on a combination of their size and compressibility. The system is
epitope independent and can capture all phenotypes of CTCs (epithelial,
mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive).
CTCs harvested from the system enable a complete picture of a cancer to be
seen; as being an intact cell they allow DNA, RNA and protein analysis as well
as cytological and morphological examination and may provide comparable
analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis
is a non-invasive process, unlike tissue biopsy, it can be repeated as often
as needed. This is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the status of a
patient's tumor. In addition, the live CTCs harvested by the Parsortix system
can be cultured, which offers the potential for testing tumor response to
drugs outside the patient.

 

The Parsortix technology is the subject of 26 granted patents in Europe, the
United States, China, Australia, Canada, India, Japan and Mexico with three
extensive families of patents are being progressed worldwide.

 

In the United States, the Parsortix(®) PC1 system has received a Class II
Classification from FDA for use with metastatic breast cancer patients. FDA
clearance is seen as the global gold standard. ANGLE's Parsortix system is the
first ever FDA cleared system for harvesting CTCs for subsequent analysis.
ANGLE has applied the IVD CE Mark to the same system for the same intended use
in Europe.

 

ANGLE has also completed three separate 200 subject clinical studies under a
programme designed to develop an ovarian cancer pelvic mass triage test, with
the results showing best in class accuracy (AUC-ROC) of 95.4% with sensitivity
of 90% and specificity of 93%. This excellent clinical result demonstrates the
utility of cells harvested by the Parsortix system, which the Company believes
is the "best sample" for liquid biopsy analysis as it recovers intact, living
cancer cells that are involved in the progression of the disease providing
prospective information.

 

ANGLE has established formal collaborations with world-class cancer centres
and major corporates such as Abbott, Philips and QIAGEN, and works closely
with leading CTC translational research customers. These Key Opinion Leaders
(KOLs) are working to identify applications with medical utility (clear
benefit to patients), and to secure clinical data that demonstrates that
utility in patient studies. The body of evidence as to the benefits of the
Parsortix system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with 80
peer-reviewed publications and numerous publicly available posters from 35
independent cancer centres, available on our website.

 

ANGLE has established clinical services laboratories in the UK and the United
States to accelerate commercialisation of the Parsortix system and act as
demonstrators to support product development. The laboratories offer services
globally to pharmaceutical and biotech customers for use of Parsortix in
cancer drug trials and, once the laboratories are accredited and tests
validated, will provide Laboratory Developed Tests (LDTs) for patient
management.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZLFBXQLZBBV